IP Library › Granted Patent US 12,540,179
Granted Patent B2
US 12,540,179 · App. 17/820,785 · Granted Feb 3, 2026

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

Inventors: Rimas J. Orentas (Seattle, WA); Dina Schneider (Potomac, MD); Boro Dropulic (Ellicott City, MD); Dimiter S. Dimitrov (Frederick, MD); Zhongyu Zhu (Frederick, MD)
Assignees: LENTIGEN TECHNOLOGY, INC.; The United States of America, as represented by the Secretary, Department of Health and Human Services
C07K16/28A61K38/1774A61P35/00C07K14/15C07K14/7051C07K14/70514C07K14/70517C07K14/70521C07K14/70525C07K14/70532C07K14/70535C07K14/70575C07K14/70589C12N15/113C12N15/62C07K2319/03C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,540,179
App. No.
17/820,785
Granted
Feb 3, 2026
Kind
B2
Abstract

Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Claims (13)

1 . A method of providing an anti-tumor immunity in a human subject comprising administering to the human subject an effective amount of an isolated T cell or an isolated natural killer (NK) cell, wherein the isolated T cell or the isolated NK cells comprise a vector comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain comprising a scFv ROR1 antigen binding domain comprising the amino acid sequence of SEQ ID NO: 2 or 8, a transmembrane domain comprising a CD8 transmembrane domain, an intracellular signaling domain comprising a functional signaling domain of 4-1BB and a CD3 zeta intracellular domain.

2 . The method of claim 1 , wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22, or an amino acid sequence having 85% identity to the amino acid sequence of SEQ ID NO: 22.

3 . The method of claim 1 , wherein the at least one extracellular antigen binding domain and the at least one intracellular signaling domain, or both are connected to the transmembrane domain by a linker or spacer domain.

4 . The method of claim 3 , wherein the linker or spacer domain is isolated from the extracellular domain of CD8, TNFRSF19, IgG4, or CD28, and is linked to the transmembrane domain.

5 . The method of claim 1 , wherein the CAR comprises the amino acid sequence of SEQ ID NO: 4, 6, 10, or 12.

6 . A method of treating cancer in a human subject, comprising administering to the human subject an effective amount of an isolated T cell or an isolated NK cell, wherein the isolated T cell or the isolated NK cells comprise a vector comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain comprising a scFv ROR1 antigen binding domain comprising the amino acid sequence of SEQ ID NO: 2 or 8, a transmembrane domain comprising a CD8 transmembrane domain, an intracellular signaling domain comprising a functional signaling domain of 4-1BB and a CD3 zeta intracellular domain.

7 . The method of claim 6 , wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22, or an amino acid sequence having 85% identity to the amino acid sequence of SEQ ID NO: 22.

8 . The method of claim 6 , wherein the at least one extracellular antigen binding domain and the at least one intracellular signaling domain, or both are connected to the transmembrane domain by a linker or spacer domain.

9 . The method of claim 8 , wherein the linker or spacer domain is isolated from the extracellular domain of CD8, TNFRSF19, IgG4, or CD28, and is linked to the transmembrane domain.

10 . The method of claim 6 , wherein the CAR comprises the amino acid sequence of SEQ ID NO: 4, 6, 10, or 12.

11 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the population of T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises the amino acid sequence of SEQ ID NO: 4, 6, 10, or 12, wherein the population of T cells are T cells of the subject having cancer.

12 . The method of claim 11 , wherein the cancer is a leukemia.

13 . The method of claim 12 , wherein the leukemia is acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphoblastic T cell leukemia (T-ALL), or acute lymphoblastic B cell leukemia (B-ALL).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2022
From: ORENTAS, RIMAS J.; SCHNEIDER, DINA; DROPULIC, BORO
To: LENTIGEN TECHNOLOGY, INC.
Reel/Frame 060965/0422 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2022
From: DIMITROV, DIMITER S.; ZHU, ZHONGYU
To: THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 060965/0640 →
Continuity (4)
Continuation 16588591 · Sep 30, 2019
Division 16179364 · Nov 2, 2018
Provisional Application 62581284 · Nov 3, 2017
Related Publication 20220389094A1 · Dec 8, 2022
References Cited (50)
US 10428141B2 · Orentas et al. · 2019 [cited by applicant]
US 11453719B2 · Orentas et al. · 2022 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20140242701A1 · Shiku · 2014 [cited by applicant]
US 20150306141A1 · Jensen et al. · 2015 [cited by applicant]
US 20170183407A1 · Cooper et al. · 2017 [cited by applicant]
US 20170226183A1 · Schiffer-Mannioui · 2017 [cited by applicant]
US 20170233472A1 · Barat et al. · 2017 [cited by applicant]
US 20180208645A1 · Orentas · 2018 [cited by applicant]
US 20190055309A1 · Orentas et al. · 2019 [cited by applicant]
US 20200102385A1 · Orentas et al. · 2020 [cited by applicant]
CN 105924533 · 2016 [cited by applicant]
JP 2014507118A · 2014 [cited by applicant]
JP 2015527070A · 2015 [cited by applicant]
JP 2017506513A · 2017 [cited by applicant]
JP 2017070299A · 2017 [cited by applicant]
JP 2017527275A · 2017 [cited by applicant]
WO WO2014031687 · 2014 [cited by applicant]
WO WO2016016343 · 2016 [cited by applicant]
WO WO2016016344 · 2016 [cited by applicant]
WO WO2016164731 · 2016 [cited by applicant]
WO WO2016201394 · 2016 [cited by applicant]
WO WO2017062820 · 2017 [cited by applicant]
WO WO2017127664 · 2017 [cited by applicant]
WO WO2018129524 · 2018 [cited by applicant]
U.S. Appl. No. 16/179,364, Orentas et al., filed Nov. 2, 2018. [cited by applicant]
U.S. Appl. No. 16/588,591, Orentas et al., filed Sep. 30, 2019. [cited by applicant]
Berger et al., “Safety of targeting ROR1 in primates with chimeric antigen receptor- modified T cells,” Cancer Immunology Research, Feb. 1, 2015, 3(2):206-216. [cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerances to Amino Acid Substitutions,” Science, 1990, 247:1306-1310. [cited by applicant]
Carbone et al., “Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen?,” Seminars in Cancer Biology, 2004, 14:399-405. [cited by applicant]
Deniger et al., “Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations,” PloS one, Jun. 1, 2015, 10(6):e01281… [cited by applicant]
Dotti et al., “Design and development of therapies using chimeric antigen receptor-expressing T cells,” Immunological Reviews, 2013, 257(1):107-126. [cited by applicant]
Eck et al., Goodman and Gilman's, McGraw-Hill, Health Profession Division, 1996, pp. 77-101. [cited by applicant]
Extended European Search Report in European Application No. 18871951.2, dated Dec. 10, 2020, 16 pages. [cited by applicant]
Gohil et al., “Preclinical development of novel humanised ROR1 targeting chimeric antigen receptor T cells and bispecific T-cell engagers,” The Lancet, Feb. 23, 2017, 389:S40, 2 pages. [cited by applicant]
Hudecek et al., “Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells,” Clinical Cancer Research, Jun. 15, 2013, 19(12):3153-64. [cited by applicant]
Hudecek et al., “The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor,” Blood, The Journal of the American Society of Hematology, Nov. 25, 2… [cited by applicant]
International Preliminary Report on Patentability in PCT Application PCT/US2018/059003, dated May 5, 2020, 6 pages. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US2018/059003, mailed Jan. 23, 2019. [cited by applicant]
Kean, et al., “Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis,” Blood, 2018, 131(24):23630-2639. [cited by applicant]
Ngo et al., “Computational complexity, protein structure prediction, and the levinthal paradox,” in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser Boston: Boston, MA, 1994, … [cited by applicant]
Park et al., “IGF1R-and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas,” Biology of Blood and Marrow Transplantation, Feb. 1, 2015, 21(2):S52-3. [cited by applicant]
Park et al., “ROR1-specific chimeric antigen receptor (CAR) NK cell immunotherapy for high risk neuroblastomas and sarcomas,” Biology of Blood and Marrow Transplantation, Mar. 1, 2017, 23(3):S136-7. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity Proc. Natl Acad. Sci. USA,” 1982, 79:1979-1983. [cited by applicant]
Schneider et al., “A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines,” Journal for Immunotherapy of Cancer, 2017, 5(1):1-17. [cited by applicant]
Uhrmacher, “Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR 1) as a diagnostic tool in chronic lymphocytic leukemia (CLL),” 2011, 35(10):1360-1366. [cited by applicant]
Voskoglou-Nomikos, et al., “Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models,” Clinical Cancer Research, 2003, 9:4227-4239. [cited by applicant]
Wang et al., “Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia,” Molecular Therapy, 2015, 23(1):184-191. [cited by applicant]
Yan et al., “Two-Amino Acid Molecular Switch in an Epithelial Morphogen That Regulates Binding to Two Distinct Receptors,” Science, 2000, 290:523-527. [cited by applicant]